You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRopivacaine
Accession NumberDB00296  (APRD00492)
TypeSmall Molecule
GroupsApproved
DescriptionRopivacaine is a local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer. Ropivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Naropin. [Wikipedia]
Structure
Thumb
Synonyms
(S)-(−)-1-propyl-2',6'-pipecoloxylidide
(S)-ropivacaine
L-N-n-propylpipecolic acid-2,6-xylidide
Ropivacaina
Ropivacaine
Ropivacainum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Naropininjection, solution5 mg/mLepidural; infiltration; perineuralGeneral Injectables & Vaccines, Inc2014-03-11Not applicableUs
Naropininjection, solution10 mg/mLepiduralFresenius Kabi USA, LLC2009-08-04Not applicableUs
Naropininjection, solution2 mg/mLepidural; infiltrationFresenius Kabi USA, LLC2009-08-04Not applicableUs
Naropininjection, solution5 mg/mLepidural; infiltration; perineuralAPP Pharmaceuticals, LLC2009-08-04Not applicableUs
Naropininjection, solution7.5 mg/mLepidural; perineuralFresenius Kabi USA, LLC2011-05-31Not applicableUs
Naropin Inj 10mg/mlsolution10 mgepiduralAstrazeneca Canada Inc1997-04-30Not applicableCanada
Naropin Inj 2mg/mlsolution2 mgblock/infiltration; epiduralAstrazeneca Canada Inc1997-04-30Not applicableCanada
Naropin Inj 5mg/mlsolution5 mgepiduralAstrazeneca Canada Inc1997-04-30Not applicableCanada
Naropin Inj 7.5mg/mlliquid7.5 mgparenteral (unspecified)Astrazeneca Canada Inc1997-04-302003-11-18Canada
Ropivacaine Hydrochloride Injectionsolution2 mgblock/infiltration; epiduralTeva Canada LimitedNot applicableNot applicableCanada
Ropivacaine Hydrochloride Injection USPsolution5 mgblock/infiltration; epiduralHospira Healthcare Corporation2010-12-14Not applicableCanada
Ropivacaine Hydrochloride Injection USPsolution10 mgblock/infiltration; epiduralHospira Healthcare Corporation2010-12-14Not applicableCanada
Ropivacaine Hydrochloride Injection, USPsolution7.5 mgnerve block; epiduralFresenius Kabi Canada LtdNot applicableNot applicableCanada
Ropivacaine Hydrochloride Injection, USPsolution2 mgblock/infiltrationHospira Healthcare CorporationNot applicableNot applicableCanada
Ropivacaine Hydrochloride Injection, USPsolution10 mgepiduralFresenius Kabi Canada LtdNot applicableNot applicableCanada
Ropivacaine Hydrochloride Injection, USPsolution2 mginfiltration; epiduralFresenius Kabi Canada LtdNot applicableNot applicableCanada
Ropivacaine Hydrochloride Injection, USPsolution5 mgblock/infiltration; epiduralFresenius Kabi Canada LtdNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ropivacaine Hydrochlorideinjection, solution10 mg/mLepiduralSagent Pharmaceuticals2014-09-23Not applicableUs
Ropivacaine Hydrochlorideinjection, solution2 mg/mLepidural; infiltrationHospira, Inc.2014-09-23Not applicableUs
Ropivacaine Hydrochlorideinjection, solution5 mg/mLparenteralSandoz Inc2014-07-24Not applicableUs
Ropivacaine Hydrochlorideinjection, solution7.5 mg/mLepidural; perineuralSagent Pharmaceuticals2014-09-23Not applicableUs
Ropivacaine Hydrochlorideinjection, solution5 mg/mLepidural; infiltrationHospira, Inc.2014-09-23Not applicableUs
Ropivacaine Hydrochlorideinjection, solution10 mg/mLparenteralSandoz Inc2014-07-24Not applicableUs
Ropivacaine Hydrochlorideinjection, solution2 mg/mLepidural; infiltration; perineuralSagent Pharmaceuticals2014-09-23Not applicableUs
Ropivacaine Hydrochlorideinjection, solution7.5 mg/mLepidural; infiltrationHospira, Inc.2014-09-23Not applicableUs
Ropivacaine Hydrochlorideinjection, solution5 mg/mLepidural; infiltration; perineuralSagent Pharmaceuticals2014-09-23Not applicableUs
Ropivacaine Hydrochlorideinjection, solution5 mg/mLepidural; infiltration; perineuralAkorn, Inc.2016-04-11Not applicableUs
Ropivacaine Hydrochlorideinjection, solution10 mg/mLepiduralHospira, Inc.2014-09-23Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ropivacaine hydrochloride
ThumbNot applicableDBSALT000902
Ropivacaine hydrochloride monohydrate
ThumbNot applicableDBSALT001585
Categories
UNII7IO5LYA57N
CAS number84057-95-4
WeightAverage: 274.4011
Monoisotopic: 274.204513464
Chemical FormulaC17H26N2O
InChI KeyInChIKey=ZKMNUMMKYBVTFN-GGYSOQFKNA-N
InChI
InChI=1/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20)/t15-/s2
IUPAC Name
(2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide
SMILES
CCCN1CCCC[[email protected]]1C(=O)NC1=C(C)C=CC=C1C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid amides
Alternative Parents
Substituents
  • Alpha-amino acid amide
  • N-arylamide
  • Piperidinecarboxylic acid
  • Piperidinecarboxamide
  • 2-piperidinecarboxamide
  • Benzenoid
  • Piperidine
  • Monocyclic benzene moiety
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed in obstetric anesthesia and regional anesthesia for surgery.
PharmacodynamicsRopivacaine, a local anesthetic agent, is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.
Mechanism of actionLocal anesthetics such as Ropivacaine block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. Specifically, they block the sodium-channel and decrease chances of depolarization and consequent action potentials. In general, the progression of anesthesia is related to the diameter, myelination and conduction velocity of affected nerve fibers.
Related Articles
AbsorptionBioavailability is 87%–98% following epidural administration.
Volume of distributionNot Available
Protein binding94%, mainly to a1-acid glycoprotein
Metabolism

Hepatic

SubstrateEnzymesProduct
Ropivacaine
3-hydroxyropivacaineDetails
Route of eliminationRopivacaine is extensively metabolized in the liver, predominantly by aromatic hydroxylation mediated by cytochrome P4501A to 3-hydroxy ropivacaine. After a single IV dose approximately 37% of the total dose is excreted in the urine as both free and conjugated 3-hydroxy ropivacaine. In total, 86% of the ropivacaine dose is excreted in the urine after intravenous administration of which only 1% relates to unchanged drug.
Half lifeApproximately 4.2 hours.
Clearance
  • 387 +/- 107 mL/min
  • unbound plasma clearance=7.2 +/- 1.6 L/min
ToxicitySystemic exposure to excessive quantities of ropivacaine mainly result in central nervous system (CNS) and cardiovascular effects – CNS effects usually occur at lower blood plasma concentrations and additional cardiovascular effects present at higher concentrations, though cardiovascular collapse may also occur with low concentrations. CNS effects may include CNS excitation (nervousness, tingling around the mouth, tinnitus, tremor, dizziness, blurred vision, seizures) followed by depression (drowsiness, loss of consciousness, respiratory depression and apnea). Cardiovascular effects include hypotension, bradycardia, arrhythmias, and/or cardiac arrest – some of which may be due to hypoxemia secondary to respiratory depression.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Ropivacaine Action PathwayDrug actionSMP00404
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9705
Blood Brain Barrier+0.9377
Caco-2 permeable+0.5912
P-glycoprotein substrateSubstrate0.8037
P-glycoprotein inhibitor IInhibitor0.8768
P-glycoprotein inhibitor IINon-inhibitor0.6339
Renal organic cation transporterNon-inhibitor0.6611
CYP450 2C9 substrateNon-substrate0.819
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.723
CYP450 1A2 substrateNon-inhibitor0.5499
CYP450 2C9 inhibitorNon-inhibitor0.9246
CYP450 2D6 inhibitorInhibitor0.8821
CYP450 2C19 inhibitorNon-inhibitor0.8773
CYP450 3A4 inhibitorNon-inhibitor0.5902
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6116
Ames testNon AMES toxic0.8507
CarcinogenicityNon-carcinogens0.8763
BiodegradationNot ready biodegradable0.9783
Rat acute toxicity2.2964 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8009
hERG inhibition (predictor II)Inhibitor0.8438
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • App pharmaceuticals llc
Packagers
Dosage forms
FormRouteStrength
Solutionepidural10 mg
Solutionblock/infiltration; epidural2 mg
Solutionepidural5 mg
Liquidparenteral (unspecified)7.5 mg
Injection, solutionepidural10 mg/mL
Injection, solutionepidural; infiltration2 mg/mL
Injection, solutionepidural; infiltration5 mg/mL
Injection, solutionepidural; infiltration7.5 mg/mL
Injection, solutionepidural; infiltration; perineural2 mg/mL
Injection, solutionepidural; infiltration; perineural5 mg/mL
Injection, solutionepidural; perineural7.5 mg/mL
Injection, solutionparenteral10 mg/mL
Injection, solutionparenteral5 mg/mL
Solutionblock/infiltration; epidural10 mg
Solutionblock/infiltration; epidural5 mg
Solutionblock/infiltration2 mg
Solutioninfiltration; epidural2 mg
Solutionnerve block; epidural7.5 mg
Prices
Unit descriptionCostUnit
Ropivacaine hcl-ns 0.5%1.84USD ml
Ropivacaine hcl 0.2% on-q pump0.99USD ml
Naropin 10 mg/ml ampule0.97USD ml
Ropivacaine hcl-ns 0.3%0.9USD ml
Ropivacaine-ns 0.1% on-q pump0.71USD ml
Naropin 7.5 mg/ml ampule0.62USD ml
Naropin 5 mg/ml vial0.58USD ml
Ropivacaine hcl-ns 0.15%0.51USD ml
Ropivacaine hcl-ns 0.125%0.48USD ml
Naropin 5 mg/ml ampule0.46USD ml
Naropin 2 mg/ml ampule0.44USD ml
Ropivacaine hcl-ns 0.1%0.39USD ml
Ropivacaine hcl-ns 0.25%0.34USD ml
Ropivacaine hcl-ns 0.2%0.29USD ml
Naropin 2 mg/ml infusion btl0.23USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1337549 No1995-11-142012-11-14Canada
CA2165446 No2005-07-052014-05-26Canada
US4870086 No1993-09-242010-09-24Us
US5670524 No1994-05-262014-05-26Us
US7828787 No2005-10-182025-10-18Us
US7857802 No2006-11-282026-11-28Us
US8118802 No2003-05-182023-05-18Us
US8162915 No2004-05-232024-05-23Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility57.6 mg/LNot Available
logP2.90HANSCH,C ET AL. (1995)
pKa8.07Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.253 mg/mLALOGPS
logP2.91ALOGPS
logP4.07ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)13.62ChemAxon
pKa (Strongest Basic)7.82ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area32.34 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity85.59 m3·mol-1ChemAxon
Polarizability32.67 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Peter Jaksch, “Process for the preparation of ropivacaine hydrochloride monohydrate.” U.S. Patent US5959112, issued February, 1970.

US5959112
General References
  1. Weinberg G, Ripper R, Feinstein DL, Hoffman W: Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. Reg Anesth Pain Med. 2003 May-Jun;28(3):198-202. [PubMed:12772136 ]
  2. Picard J, Meek T: Lipid emulsion to treat overdose of local anaesthetic: the gift of the glob. Anaesthesia. 2006 Feb;61(2):107-9. [PubMed:16430560 ]
  3. Rosenblatt MA, Abel M, Fischer GW, Itzkovich CJ, Eisenkraft JB: Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology. 2006 Jul;105(1):217-8. [PubMed:16810015 ]
External Links
ATC CodesN01BB09
AHFS Codes
  • 72:00.00
PDB EntriesNot Available
FDA labelDownload (274 KB)
MSDSDownload (57 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ropivacaine is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Ropivacaine can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Ropivacaine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Alprazolam.
AmiodaroneThe metabolism of Ropivacaine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amperozide.
AprepitantThe serum concentration of Ropivacaine can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Aripiprazole.
ArtemetherThe metabolism of Ropivacaine can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Asenapine.
AtazanavirThe metabolism of Ropivacaine can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Ropivacaine can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Azaperone.
AzelastineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ropivacaine.
AzithromycinThe metabolism of Ropivacaine can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Benzyl alcohol.
BetaxololThe metabolism of Ropivacaine can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Ropivacaine can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Ropivacaine can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Ropivacaine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Ropivacaine can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.
BrimonidineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Bupivacaine.
BuprenorphineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Buprenorphine.
BupropionThe metabolism of Ropivacaine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ropivacaine.
ButacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Butorphanol.
CaffeineThe metabolism of Ropivacaine can be decreased when combined with Caffeine.
CarbamazepineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Carisoprodol.
CelecoxibThe metabolism of Ropivacaine can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Ropivacaine can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chloroprocaine.
ChloroquineThe metabolism of Ropivacaine can be decreased when combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorphenamine.
ChlorpromazineThe metabolism of Ropivacaine can be decreased when combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Ropivacaine can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Ropivacaine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Ropivacaine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cinchocaine.
CiprofloxacinThe serum concentration of Ropivacaine can be increased when it is combined with Ciprofloxacin.
CitalopramThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Citalopram.
CitalopramThe metabolism of Ropivacaine can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Ropivacaine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Ropivacaine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clidinium.
ClobazamThe metabolism of Ropivacaine can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Ropivacaine is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clomipramine.
ClomipramineThe metabolism of Ropivacaine can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clonidine.
ClopidogrelThe metabolism of Ropivacaine can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clorazepate.
ClotrimazoleThe metabolism of Ropivacaine can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Ropivacaine can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clozapine.
CobicistatThe serum concentration of Ropivacaine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Codeine.
ConivaptanThe serum concentration of Ropivacaine can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Ropivacaine can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cyclobenzaprine.
CyclosporineThe metabolism of Ropivacaine can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Ropivacaine can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Ropivacaine can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dapoxetine.
DarifenacinThe metabolism of Ropivacaine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Ropivacaine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Ropivacaine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Ropivacaine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Ropivacaine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Desflurane.
DesipramineThe metabolism of Ropivacaine can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Detomidine.
DexamethasoneThe serum concentration of Ropivacaine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dexmedetomidine.
DextromoramideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Diazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Ropivacaine can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dihydromorphine.
DiltiazemThe metabolism of Ropivacaine can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Ropivacaine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Doxepin.
DoxorubicinThe metabolism of Ropivacaine can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Ropivacaine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.
DoxylamineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Ropivacaine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.
DronedaroneThe metabolism of Ropivacaine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Drotebanol.
DuloxetineThe metabolism of Ropivacaine can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Ropivacaine is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Ropivacaine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Efavirenz.
EliglustatThe metabolism of Ropivacaine can be decreased when combined with Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ropivacaine.
EntacaponeThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Entacapone.
EnzalutamideThe serum concentration of Ropivacaine can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Ropivacaine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Ropivacaine can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Eszopiclone.
EthanolRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Ropivacaine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ropivacaine.
EthosuximideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ropivacaine.
EtoperidoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Etorphine.
EtravirineThe serum concentration of Ropivacaine can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fentanyl.
FexofenadineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Flibanserin.
FluconazoleThe metabolism of Ropivacaine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluoxetine.
FluoxetineThe metabolism of Ropivacaine can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluticasone Propionate.
FluvoxamineThe serum concentration of Ropivacaine can be increased when it is combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluvoxamine.
FosamprenavirThe metabolism of Ropivacaine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Ropivacaine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fospropofol.
Fusidic AcidThe serum concentration of Ropivacaine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Ropivacaine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Halazepam.
HaloperidolThe metabolism of Ropivacaine can be decreased when combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Hexobarbital.
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Ropivacaine.
HydrocodoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Hydromorphone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.
HydroxyzineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Hydroxyzine.
IdelalisibThe serum concentration of Ropivacaine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Iloperidone.
ImatinibThe metabolism of Ropivacaine can be decreased when combined with Imatinib.
ImipramineThe metabolism of Ropivacaine can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Indalpine.
IndinavirThe metabolism of Ropivacaine can be decreased when combined with Indinavir.
IsavuconazoniumThe metabolism of Ropivacaine can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Isoflurane.
IsoniazidThe metabolism of Ropivacaine can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Ropivacaine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Ropivacaine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Ropivacaine can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ketobemidone.
KetoconazoleThe metabolism of Ropivacaine can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levorphanol.
LidocaineThe metabolism of Ropivacaine can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Lidocaine.
LithiumThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Lofentanil.
LopinavirThe metabolism of Ropivacaine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ropivacaine.
LorcaserinThe metabolism of Ropivacaine can be decreased when combined with Lorcaserin.
LovastatinThe metabolism of Ropivacaine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Ropivacaine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Ropivacaine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Ropivacaine can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Ropivacaine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Meprobamate.
MesoridazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Metaxalone.
MethadoneThe metabolism of Ropivacaine can be decreased when combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methylphenobarbital.
MetoprololThe metabolism of Ropivacaine can be decreased when combined with Metoprolol.
MetyrosineRopivacaine may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Ropivacaine can be decreased when combined with Mexiletine.
MidazolamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Midazolam.
MifepristoneThe metabolism of Ropivacaine can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.
MirabegronThe metabolism of Ropivacaine can be decreased when combined with Mirabegron.
MirtazapineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ropivacaine.
MitotaneThe serum concentration of Ropivacaine can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Ropivacaine can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ropivacaine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.
NabiloneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nabilone.
NafcillinThe serum concentration of Ropivacaine can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nalbuphine.
NefazodoneThe metabolism of Ropivacaine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Ropivacaine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Ropivacaine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Ropivacaine can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Ropivacaine can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Ropivacaine can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Olanzapine.
OlaparibThe metabolism of Ropivacaine can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Opium.
OrphenadrineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ropivacaine.
OsanetantThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Osanetant.
OsimertinibThe serum concentration of Ropivacaine can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxymorphone.
PalbociclibThe serum concentration of Ropivacaine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Paliperidone.
PanobinostatThe metabolism of Ropivacaine can be decreased when combined with Panobinostat.
ParaldehydeRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Ropivacaine.
ParoxetineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Paroxetine.
ParoxetineThe metabolism of Ropivacaine can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Ropivacaine can be decreased when it is combined with Peginterferon alfa-2b.
PentazocineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pentobarbital.
PerampanelThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pethidine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pomalidomide.
PosaconazoleThe metabolism of Ropivacaine can be decreased when combined with Posaconazole.
PramipexoleRopivacaine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ropivacaine.
PrilocaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Procaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Prochlorperazine.
PromazineThe metabolism of Ropivacaine can be decreased when combined with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Proparacaine.
PropofolThe serum concentration of Ropivacaine can be increased when it is combined with Propofol.
PropofolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Ropivacaine is combined with PSD502.
QuazepamThe serum concentration of Ropivacaine can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Quetiapine.
QuinidineThe metabolism of Ropivacaine can be decreased when combined with Quinidine.
QuinineThe metabolism of Ropivacaine can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ramelteon.
RanolazineThe metabolism of Ropivacaine can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ropivacaine.
RifabutinThe metabolism of Ropivacaine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Ropivacaine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Ropivacaine can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Risperidone.
RitonavirThe metabolism of Ropivacaine can be decreased when combined with Ritonavir.
RolapitantThe metabolism of Ropivacaine can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Romifidine.
RopiniroleRopivacaine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Ropivacaine can be decreased when combined with Ropinirole.
RotigotineRopivacaine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ropivacaine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Ropivacaine is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Ropivacaine can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Secobarbital.
SertindoleThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sertraline.
SertralineThe metabolism of Ropivacaine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sevoflurane.
SildenafilThe metabolism of Ropivacaine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Ropivacaine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Ropivacaine can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sodium oxybate.
SorafenibThe metabolism of Ropivacaine can be decreased when combined with Sorafenib.
St. John's WortThe serum concentration of Ropivacaine can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sufentanil.
SulfisoxazoleThe metabolism of Ropivacaine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sulpiride.
SuvorexantThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tasimelteon.
Technetium Tc-99m tilmanoceptRopivacaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.
TelaprevirThe metabolism of Ropivacaine can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Ropivacaine can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ropivacaine.
TenofovirThe metabolism of Ropivacaine can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Ropivacaine can be decreased when combined with Terbinafine.
TeriflunomideThe serum concentration of Ropivacaine can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tetrodotoxin.
ThalidomideRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ropivacaine.
TheophyllineThe metabolism of Ropivacaine can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Thioridazine.
ThiotepaThe metabolism of Ropivacaine can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tiagabine.
TiclopidineThe metabolism of Ropivacaine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tiletamine.
TipranavirThe metabolism of Ropivacaine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tizanidine.
TocilizumabThe serum concentration of Ropivacaine can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ropivacaine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe metabolism of Ropivacaine can be decreased when combined with Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Triflupromazine.
TrimipramineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Valproic Acid.
VemurafenibThe serum concentration of Ropivacaine can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Ropivacaine can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Ropivacaine can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Vilazodone.
VoriconazoleThe metabolism of Ropivacaine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zimelidine.
ZiprasidoneThe metabolism of Ropivacaine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zolpidem.
ZonisamideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms.
Gene Name:
SCN10A
Uniprot ID:
Q9Y5Y9
Molecular Weight:
220623.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Liu BG, Zhuang XL, Li ST, Xu GH: The effects of ropivacaine on sodium currents in dorsal horn neurons of neonatal rats. Anesth Analg. 2000 May;90(5):1034-8. [PubMed:10781449 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Arlander E, Ekstrom G, Alm C, Carrillo JA, Bielenstein M, Bottiger Y, Bertilsson L, Gustafsson LL: Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. Clin Pharmacol Ther. 1998 Nov;64(5):484-91. [PubMed:9834040 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 02:14